HI-TRON Mainz joins Collaborative Research Center SFB 1292
HI-TRON Mainz is now part of the newly funded third phase of the DFG Collaborative Research Center SFB 1292, “Targeting converging mechanisms of inefficient immunity in cancer and chronic infections.”
The consortium brings together leading experts to unravel how tumors and persistent viral infections evade immune responses, aiming to pave the way for improved immunotherapies.
Building on major insights from previous funding periods—ranging from the impact of tumor metabolism and tissue acidification on immune function to the discovery of inhibitors that block metastasis or viral replication—SFB 1292 continues to bridge fundamental immunology with clinical translation.
The next funding period (2026–2029) is supported by the DFG with €13.9 million and unites researchers from Universitätsmedizin Mainz, HI-TRON, TRON, and multiple national partner institutions.
